Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 64Neoplasms 8Sarcoma 6Ovarian Neoplasms 6Squamous Cell Carcinoma of Head and Neck 5Neoplasm Metastasis 5Sarcoma, Ewing 4Multiple Myeloma 4Lymphoma, Non-Hodgkin 4Glioma 4Carcinoma, Non-Small-Cell Lung 4Rhabdomyosarcoma 3Rhabdoid Tumor 3Prostatic Neoplasms 3Osteosarcoma 3Neuroblastoma 3Melanoma 3Medulloblastoma 3Lymphoma 3Liposarcoma 3Endometrial Neoplasms 3Colorectal Neoplasms 3Colonic Neoplasms 3Carcinoma, Renal Cell 3Wilms Tumor 2Rectal Neoplasms 2Pancreatic Neoplasms 2Neuroectodermal Tumors, Primitive, Peripheral 2Lung Neoplasms 2Kidney Neoplasms 2

Interventions

Tamoxifen 2Paclitaxel 2pyrotinib 1pembrolizumab 1palbociclib 1iniparib 1darolutamide 1Thioctic Acid 1Pentoxifylline 1Metformin 1Letrozole 1Doxorubicin 1Cyclophosphamide 1Capecitabine 1Aromatase Inhibitors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Breast Cancer Female × palbociclib × Clear all
NCT03065621 2023-04-19

NeoRHEA

Jules Bordet Institute

Phase 2 Completed
100 enrolled
Breast

Breast Cancer Female

Data powered by HemOnc (CC BY 4.0) Colophon âš¡